Capecitabine/oxaliplatin Reactions 1680, p79 - 2 Dec 2017 Pyogenic granuloma: case report A 73-year-old man developed pyogenic granuloma during treatment with capecitabine and oxaliplatin. The man, who was diagnosed with adenocarcinoma of the gastroesophageal junction, started receiving combination therapy with capecitabine and oxaliplatin [route and dosage not stated]. One week after the start of treatment, the skin nodules appeared on his fingers. He was referred for assessment of haemorrhagic nodules appeared on his fingers. He had no history of trauma. Physical examination revealed a pale-reddish, dome-shaped, 5mm nodules on the index fingers and left thumb. Additionally, palmar erythema with tingling sensation was reported. The man’s nodules appearing on his fingers were removed surgically. A histopathological study showed presence of well- circumscribed proliferation of small capillaries in a lobular fashion in the dermis. Based on the medical history and these findings, he was diagnosed with pyogenic granulomas caused due to capecitabine therapy. No reappearance was seen three months after resection. Author comment: ’’Our patient noted the lesions approximately 1 week after the treatment, suggesting that [pyogenic granulomas]/[pyogenic granulomas]-like lesions might have developed in a relatively short period of time after the administration of capecitabine. Although we could find no report of [pyogenic granulomas] caused by oxaliplatin, we cannot exclude the possibility of oxaliplatin as a responsible agent.’’ Fujiwara C, et al. Pyogenic granuloma possibly associated with capecitabine therapy. Journal of Dermatology 44: 1329-1331, No. 11, Nov 2017. Available from: URL: - Japan 803284976 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site


You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial